ABVX Abivax SA

DGAP-News: Abivax announces the release of its 2020 half-year financial report

DGAP-News: ABIVAX / Key word(s): Half Year Results
Abivax announces the release of its 2020 half-year financial report

30.09.2020 / 18:00
The issuer is solely responsible for the content of this announcement.

Abivax announces the release of its 2020 half-year financial report


PARIS, France, September 30, 2020 - 06:00 p.m. (CET) - Abivax (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer, today announces the publication of its 2020 half-year financial report. This document is available in electronic version on the website of the company () and on the website of the French financial markets authority, AMF ().


About Abivax ()
Abivax, a clinical stage biotechnology company, is mobilizing the body's natural immune machinery to treat patients with autoimmune diseases, viral infections, and cancer. Abivax is listed on Euronext compartment C (ISIN: FR0012333284 - Mnémo: ABVX). Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, ABX464 to treat severe inflammatory diseases, and ABX196 to treat hepatocellular carcinoma.

More information on the company is available at . Follow us on Twitter @ABIVAX_.

******

Contacts

Abivax
Finance Department
Didier Blondel

41		 Investors
LifeSci Advisors
Chris Maggos

 Press Relations & Investors Europe
MC Services AG
Anne Hennecke

22

Public Relations France
Actifin
Ghislaine Gasparetto

24
Public Relations France
DGM Conseil
Thomas Roborel de Climens

84
Public Relations USA
Rooney Partners LLC
Marion Janic

30.09.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

1137910  30.09.2020 

fncls.ssp?fn=show_t_gif&application_id=1137910&application_name=news&site_id=research_pool
EN
30/09/2020

Underlying

ABVXAbivax SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Abivax SA

 PRESS RELEASE
Free
ABVX ABIVAX SA

Abivax to be Added to Nasdaq Biotechnology Index

Abivax to be Added to Nasdaq Biotechnology Index Abivax to be Added to Nasdaq Biotechnology Index PARIS, France – December 18, 2025 – 10:05 pm CET – (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced that it will be added to the Nasdaq Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 22, 2025. Didie...

December 18, 2025 1 EN
 PRESS RELEASE
Free
ABVX ABIVAX SA

Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in I...

Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings Breadth of Scientific Evidence: The acceptance of 1 oral presentation, 5 digital oral presentations and 16 posters reflect an expanding dataset for obefazimod, including additional efficacy, safety, and cytokine data from the Phase 3 ABTE...

December 17, 2025 1 EN
 PRESS RELEASE
Free
ABVX ABIVAX SA

Abivax Presents Third Quarter 2025 Financial Results

Abivax Presents Third Quarter 2025 Financial Results Abivax Presents Third Quarter 2025 Financial Results Cash and cash equivalents of EUR 589.7 (as of September 30, 2025) with a cash runway into Q4 2027 PARIS, France, December 15, 2025, 10:05 p.m. CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, announced today its key financial info...

December 15, 2025 1 EN
 PRESS RELEASE
Free
ABVX ABIVAX SA

Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTEC...

Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely Active Ulcerative Colitis Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely Active Ulcerative Colitis Improvements across all patient reported outcomes (PROs) were observed from baseline to Week 8 in all PRO instruments utilized in the ABTECT ...

November 3, 2025 1 EN
Free Trial
ABVX ABIVAX SA

Abivax: 1 director

A director at Abivax sold 1,200,000 shares at 94.085EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...

11/01/25 November 1, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch